Compare BHR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHR | SGMT |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.9M | 164.6M |
| IPO Year | N/A | 2021 |
| Metric | BHR | SGMT |
|---|---|---|
| Price | $2.51 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | ★ 398.2K | 352.1K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 8.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,523.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.80 | $1.73 |
| 52 Week High | $3.19 | $11.41 |
| Indicator | BHR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 44.24 |
| Support Level | $2.46 | $4.97 |
| Resistance Level | $2.70 | $6.49 |
| Average True Range (ATR) | 0.13 | 0.34 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 32.93 | 19.47 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.